Comparison of two scores of short term serious outcome in COPD patients

Chronic Obstructive Pulmonary Disease (COPD) related visits to the emergency department have increased substantially during the past decade. An important challenge facing emergency physicians when treating COPD patients is deciding on disposition. The aim of this study was to evaluate Integrated Pulmonary Index scoring to guide the disposition decisions of emergency physicians by comparing its compatibility with Ottawa COPD Risk Score.
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Source Type: research

Related Links:

Conclusions/Implications for Practice: Our findings confirmed a deterioration in pulmonary function in smokers who did not perform moderate or vigorous PA. The level of PA performed was positively related to pulmonary function in smokers, whereas in nonsmokers, improvements were only significant in LA–CA.
Source: Journal of Nursing Research - Category: Nursing Tags: ORIGINAL ARTICLES Source Type: research
Background Males represent a significant portion of patients undergoing abdominal contouring. Despite this, there are few studies examining the implication of gender on complications. Objective The aim of this study was to examine the association between gender and early postoperative outcomes in patients undergoing abdominal contouring procedures. Methods The American College of Surgeons National Surgical Quality Improvement Program database (2006–2016) was queried to identify subjects undergoing panniculectomy or abdominoplasty. Minor and major complications were identified. Operative time and length of hos...
Source: Annals of Plastic Surgery - Category: Cosmetic Surgery Tags: Review Paper Source Type: research
The first reusable, propellant-free inhaler is now available for patients with asthma and COPD, in line with NHS plans to reduce its carbon footprint and plastic waste.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Point-of-care C-reactive protein testing reduces antibiotic use in people with acute COPD exacerbations, a study published in The New England Journal of Medicine has shown.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
The National Heart, Lung, and Blood Institute (NHLBI) is holding a workshop, COPD National Action Plan: Tracking Our Progress, on November 13, 2019, at the National Institutes of Health in Bethesda, Maryland. We ’ ll discuss the progress the COPD community has made toward implementing the goals and objectives in the COPD National Action Plan, and how to collectively track these efforts. During the morning, panel presentations will discuss federal agency efforts to address COPD, national initiatives by supporting organizations, and approaches targeted to individual audiences. Afternoon discussions will gather feedbac...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
Our clients are some of the leading innovators in providing therapies for medical conditions ranging from COPD to atrial fibrillation and lung cancer. They depend on a competent team to deliver timely solutions for scaling the manufacturing process in order to deliver life-saving medical solutions. Often times, the manufacturing transfer of the device requires the use of an existing design package, posing new challenges for optimizing an integrated design team to bring the product to market quickly and efficiently. The manufacturing transfer process is critical to a company’s success. These five steps ser...
Source: MDDI - Category: Medical Devices Authors: Tags: Contract Manufacturing Source Type: news
Condition:   COPD Interventions:   Drug: Ensifentrine 100mcg;   Drug: Ensifentrine 300mcg;   Drug: Ensifentrine 1000mcg;   Drug: Ensifentrine 3000mcg;   Drug: Ensifentrine 6000mcg;   Drug: Placebos Sponsors:   Verona Pharma plc;   Iqvia Pty Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   COPD Exacerbation;   CHF;   OSA;   COPD Intervention:   Diagnostic Test: Multidimensional Dyspne Profile Sponsor:   Institut für Pneumologie Hagen Ambrock eV Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COPD Interventions:   Drug: Ensifentrine 100mcg;   Drug: Ensifentrine 300mcg;   Drug: Ensifentrine 1000mcg;   Drug: Ensifentrine 3000mcg;   Drug: Ensifentrine 6000mcg;   Drug: Placebos Sponsors:   Verona Pharma plc;   Iqvia Pty Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   COPD Exacerbation;   CHF;   OSA;   COPD Intervention:   Diagnostic Test: Multidimensional Dyspne Profile Sponsor:   Institut für Pneumologie Hagen Ambrock eV Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Obstructive Pulmonary | Emergency Medicine | Study